We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Preparation, quality control, and absorbed dose estimation of <sup>89</sup>Zr-DFO-Cetuximab for imaging of EGFR-expressing tumors.
- Authors
Zolghadri, Samaneh; Mohammadpour-Ghazi, Fatemeh; Yousefnia, Hassan
- Abstract
In this study, 89Zr-DFO-Cetuximab was prepared under the optimized conditions with a radiochemical purity > 99%, and a specific activity of 185 GBq g−1. Cellular studies on EGFR + SW480 colon cancer and EGFR-CHO cell lines were performed, indicating the remarkable capability of 89Zr-DFO-Cetuximab for binding to the low EGFR-expressing cells. High accumulation was observed in tumors of nude mice-bearing SW480 cell lines. Human absorbed dose estimation showed the liver receives the highest absorbed dose (0.94 mGy MBq−1). This radiopharmaceutical is the suitable PET agent for imaging of EGFR-expressing tumors at 72–120 h after injection.
- Subjects
ABSORBED dose; QUALITY control; RADIOCHEMICAL purification; COLON cancer; POSITRON emission tomography; DOSE-response relationship (Radiation)
- Publication
Journal of Radioanalytical & Nuclear Chemistry, 2024, Vol 333, Issue 6, p2639
- ISSN
0236-5731
- Publication type
Article
- DOI
10.1007/s10967-024-09486-7